RT Book, Section A1 Smith, Matthew R. A2 Chabner, Bruce A. A2 Longo, Dan L. SR Print(0) ID 1127647081 T1 Osteoclast-Targeted Therapy: Bisphosphonates and Denosumab T2 Harrison's Manual of Oncology, 2e YR 2016 FD 2016 PB McGraw-Hill Education PP New York, NY SN 9780071793254 LK hemonc.mhmedical.com/content.aspx?aid=1127647081 RD 2024/10/04 AB Bone metastases are a major cause of morbidity in patients with a variety of malignancies including multiple myeloma, breast cancer, and prostate cancer (1). Bone metastases are often described as osteoblastic or osteolytic based on their radiographic appearance. Osteoblastic and osteolytic bone disease represent two extremes of a spectrum, however, and osteoclast number and activity are increased in most bone metastases, including typical osteoblastic metastases from prostate cancer. Pathological activation of osteoclasts appears to play a central role in disease-related skeletal complications.